Over the past two decades, advancements in the industry have shifted how we diagnose, classify and ultimately treat certain cancers according to an individual’s molecular profile – a practice known as precision medicine. What does this transformative approach, and the diagnostics needed to achieve it, mean for the oncology industry, and most importantly, for patients with cancer? What gaps still remain, and how can stakeholders come together to address them?
During a panel discussion for The Atlantic, Takeda Oncology’s Christine Ward, PhD, Head, Oncology and Cell Therapy Precision & Translational Medicine, met with Garret Hampton, President, Oncology Clinical Sequencing Division, Thermo Fisher Scientific, and Jeff Allen, President, Friends of Cancer Research, to answer these important questions and discuss what’s needed to continue advancing this field of medicine.
Advancing the Future of Oncology Through Precision Medicine: A Discussion with Christine Ward, Garret Hampton and Jeff Allen
Watch Takeda Oncology’s Christine Ward, PhD, Head, Oncology and Cell Therapy Precision & Translational Medicine, facilitate a panel discussion for The Atlantic
Read more about Christine’s takeaways from this session by visiting LinkedIn.